Related Experiment Video
Updated: Jul 10, 2026
08:26
Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
Published on: June 14, 2018
Solid-phase PEGylation of recombinant interferon alpha-2a for site-specific modification: process performance,
Byung Kook Lee1, Jin Sook Kwon, Hyung Jin Kim
1Bioprocessing Research Laboratory, Department of Chemical Engineering, Hanyang University, Ansan, Korea.
Bioconjugate Chemistry
|October 19, 2007
Summary
Solid-phase PEGylation of recombinant interferon alpha-2a offers advantages over solution-phase methods. This study demonstrates efficient N-terminal mono-PEGylation and purification, overcoming common challenges and improving protein stability.
Area of Science:
- Bioconjugation Chemistry
- Protein Engineering
- Pharmaceutical Sciences
Background:
- Conventional solution-phase PEGylation of proteins like interferon (IFN) can lead to random multi-PEGylation and purification challenges.
- Solid-phase techniques offer potential for controlled protein modification and simplified downstream processing.
Purpose of the Study:
- To investigate the feasibility and efficiency of solid-phase N-terminal mono-PEGylation of recombinant human interferon alpha-2a (rhIFN-alpha-2a).
- To assess the impact of PEGylation on rhIFN-alpha-2a bioactivity, antibody binding, and stability.
- To overcome limitations of solution-phase PEGylation, including uncontrolled PEGylation and purification difficulties.
Main Methods:
- Adsorption of rhIFN-alpha-2a to a cation-exchange resin for solid-phase immobilization.
- Reductive alkylation for N-terminal PEGylation using 5, 10, and 20 kDa methoxy-PEG aldehydes (mPEG).
- Salt gradient elution for simultaneous purification of mono-PEGylated rhIFN-alpha-2a from unreacted species.
- N-terminus sequencing and MALDI-TOF mass spectrometry for structural confirmation.
- Cell proliferation assays and surface plasmon resonance (SPR) biosensing to evaluate bioactivity and binding.
Main Results:
- Successful integration of mono-PEGylation and purification into a single chromatographic step.
- Mono-PEGylation yields ranged from 50% to 65%, dependent on mPEG molecular weight.
- Confirmed exclusive N-terminal conjugation of PEG via sequencing and mass spectrometry.
- Observed a decrease in antiviral activity and antibody binding with increasing PEG molecular weight.
- Demonstrated significant improvements in trypsin resistance and thermal stability of PEGylated IFN.
Conclusions:
- Solid-phase PEGylation provides a robust method for controlled N-terminal modification of rhIFN-alpha-2a.
- This approach effectively addresses issues of random PEGylation and purification complexity inherent in solution-phase methods.
- While bioactivity may be reduced, enhanced stability offers therapeutic advantages, warranting further investigation for drug development.
More Related Videos
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...